indexado en
  • Base de datos de revistas académicas
  • Abrir puerta J
  • Genamics JournalSeek
  • Claves Académicas
  • DiarioTOCs
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • Directorio de publicaciones periódicas de Ulrich
  • Biblioteca de revistas electrónicas
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catálogo en línea SWB
  • Biblioteca Virtual de Biología (vifabio)
  • Publón
  • Fundación de Ginebra para la Educación e Investigación Médica
  • pub europeo
  • Google Académico
Comparte esta página
Folleto de diario
Flyer image

Abstracto

Severe Asthma: Anti-IgE or Anti-IL-5?

Petros Bakakos and Stelios Loukides

Asthma is a common disease affecting more than 300 million people worldwide [1]. According to the recent ERS/ATS consensus severe asthma is defined as asthma that requires treatment with high dose Inhaled corticosteroids (ICS) plus one more controller (and/or oral corticosteroids) in order to be controlled or remains uncontrolled despite the above treatment or becomes uncontrolled with the reduction of high dose ICS or oral corticosteroids [2]. It is a prerequisite that the correct diagnosis of asthma has been confirmed and comorbidities have been identified and treated properly [2]. It is also extremely important to check inhaler technique and ensure good adherence to treatment. Current GINA document suggests that a referral to a specialist with expertise in the management of severe asthma is strongly encouraged for patients not controlled with treatment step 3 [1].